[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stent-related-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stent-related-symptoms":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100590391","phase-3-comparison-of-alpha-blockers-terazosin-and-tamsulosin-in-reducing-ureteral-stent-related-symptoms-100590391",false,"NCT06966804","Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms","Efficacy of Alpha Blockers (Terazosin vs Tamsulosin) in Reducing Ureteral Stent Related Symptoms - An Open-label, Randomized Controlled Trial","TRAM","Inclusion Criteria:\n\n1. Malaysian age 18 years old and above.\n2. Able to provide written informed consent to participate in the trial.\n3. Willing to comply with study procedures.\n4. Unilateral intracorporeal lithotripsy procedure with ureteral stent placement for uncomplicated ureteric or renal calculi\n\nExclusion Criteria:\n\n1. Known comorbidity that increase the risk of complication\n\n   1. Prostate pathology: Benign prostate hyperplasia, prostatitis, prostatic carcinoma\n   2. Bladder pathology: Bladder tumor, stone, overactive bladder\n   3. Ureteral abnormality\u002F trauma, urethral stricture\n   4. Concomitant urinary tract infection\n   5. Orthostatic hypotension\n   6. Solitary kidney\n2. Previous pelvic\u002F gynaecological surgery\n3. Patient is concomitantly receiving treatment from a pain clinic for chronic pain management.\n4. Pregnancy (for women of childbearing potential)\n5. Known history of allergic reactions to tamsulosin or terazosin\n6. Patient is concomitantly taking warfarin or H2 receptor blockers\n7. Patients with clinical condition(s) judged by the researcher\u002F clinician to be unsuitable for participation in the study","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this clinical trial is to compare how well Terazosin, Tamsulosin and standard care (no alpha-blocker) reduce urinary symptoms after ureteral stent placement. This trial also learn about the safety of these two study medications.\n\nMain objective:\n\n• To compare how well Terazosin, Tamsulosin and standard of care reduce post-stenting urinary symptoms.\n\nSecondary objectives:\n\n* To compare painkiller use among the groups.\n* To assess differences in Body pain, General health, Work performance, Sexual matters, and Additional problems using a questionnaire (USSQ).\n* To assess differences in side effects.\n\nAfter stent placement, subjects will be randomly assigned to one of three groups:\n\n1. Terazosin (alpha-blocker) for 14 days\n2. Tamsulosin (alpha-blocker) for 14 days\n3. Standard of care (no alpha-blocker). All subjects will be discharged with standard pain-killers and a diary to track usage. Subjects in Terazosin and Tamsulosin groups will receive respective study medications to complete 14 days course of treatment.\n\nFollow-Up:\n\n* Day 7: A phone call will check medication use and any side effects.\n* Day 15: Clinic visit for stent removal (standard practice). Subjects will complete the USSQ questionnaire, and medication compliance will be reviewed.\n\nEnd of study: Final phone call to check for any additional side effects.",[27],"Stent Related Symptoms",[29,30,31,32,33],"alpha blockers","ureteral stent-related symptoms","tamsulosin","terazosin","USSQ","RECRUITING","2025-08-28",{"date":37,"type":38},"2025-09-05","ACTUAL",{"date":40,"type":38},"2025-06-01",{"date":42,"type":21},"2026-05-31",{"name":44,"class":45},"Penang Hospital, Malaysia","OTHER_GOV",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100579946","comparison-of-stent-related-symptoms-regular-double-j-stent-vs-comfi-j-stent-100579946","NCT06830902","Comparison of Stent-Related Symptoms: Regular Double J Stent vs. Comfi J Stent","Comparison of Stent Related Symptoms Between Regular Double J Stent Versus Comfi J Stent: A Single Blinded Randomized Controlled Trial","COMFIJ","Inclusion Criteria:\n\n* Eligible participants were adult patients (aged 18-80 years) who underwent unilateral retrograde ureteroscopy (URS) lithotripsy for stone disease\n* Retrograde intrarenal surgery (RIRS) lithotripsy with planned ureteric stent insertion for urinary tract stones\n\nExclusion Criteria:\n\n* Concomitant use of a-blockers, anticholinergics, corticosteroids, calcium channel blockers, and analgesics\n* Undergoing percutaneous nephrolithotomy, open ureteric surgery or laparoscopic ureteric surgery, including ureterolithotomy\n* Neurogenic bladder, Overactive bladder syndrome, and neurological and psychiatric diseases\n* Preoperative febrile Urinary Tract Infection (UTI)\n* Pregnancy or breastfeeding;\n* A single kidney\n* Moderate or severe cardiovascular or cerebrovascular disease\n* Hepatic dysfunction\n* History of pelvic surgery or irradiation\n* History of bladder or prostate surgery\n* Other acute medical conditions (including acute pancreatitis, acute gastroenteritis, musculoskeletal disorders) that might influence the USSQ pain score\n* Allergy to any medication","80 Years",{"count":56,"type":21},100,[58],"NA","A prospective, single-blinded, randomized controlled trial conducted at a single center to compare stent related symptoms between two different stents using Ureteral Stent Symptom Questionnaire (USSQ) scores , Visual Analog Scale (VAS) pain scores.",[27],"NOT_YET_RECRUITING","2025-02-18",{"date":64,"type":38},"2025-02-19",{"date":66,"type":21},"2025-02-15",{"date":68,"type":21},"2025-09-15",{"name":70,"class":45},"Bir Hospital",1]